NIOX Group PLC
NIOX
Company Profile
Business description
NIOX Group PLC is a medical device company that develops a range of therapies for asthma, chronic obstructive pulmonary disease, and allergy. The company has a single operating segment: NIOX. The NIOX segment relates to the portfolio of products used to improve asthma diagnosis and management by measuring fractional exhaled nitric oxide (FeNO). Geographically, it derives a majority of its revenue from the Asia Pacific and also has a presence in the European Union, the United States, the United Kingdom, and the Rest of the world.
Contact
Edmund Halley Road
Hayakawa Building
The Oxford Science Park
OxfordOX4 4GB
GBRT: +44 3303309356
Sector
Healthcare
Stock type
Defensive
Industry
Medical Devices
Fiscal Year End
31 December 2025
Employees
92
Stocks News & Analysis
stocks
Is our ASX best idea still attractive after shares surge?
Shares rose over 21% following the results.
stocks
Unconventional wisdom: A controversial income pick
Rigid definitions of income and growth shares may be holding investors back.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,743.00 | 37.30 | -0.42% |
| CAC 40 | 7,973.03 | 34.59 | -0.43% |
| DAX 40 | 21,787.00 | 115.42 | -0.53% |
| Dow JONES (US) | 44,303.40 | 444.23 | -0.99% |
| FTSE 100 | 8,700.53 | 26.75 | -0.31% |
| HKSE | 21,453.32 | 319.78 | 1.51% |
| NASDAQ | 19,523.40 | 268.59 | -1.36% |
| Nikkei 225 | 38,764.32 | 22.70 | -0.06% |
| NZX 50 Index | 12,872.90 | 29.29 | -0.23% |
| S&P 500 | 6,025.99 | 57.58 | -0.95% |
| S&P/ASX 200 | 8,477.40 | 34.00 | -0.40% |
| SSE Composite Index | 3,313.75 | 10.08 | 0.31% |